The 2020 results from trials of minimally invasive glaucoma surgery (MIGS) device MINIjectTM will be presented at the upcoming European Glaucoma Society (EGS) annual meeting on 12-13 December. The consistently positive data showed outstanding results of intraocular pressure (IOP) and medication reduction in patients with open angle glaucoma, and a positive safety profile across trials.
The final two-year outcomes from the STAR-I clinical trial will be presented by Professor Doctor Philippe Denis, one of the trial investigators and Chair of the Department of Ophthalmology of Croix-Rousse University Hospital of Lyon, France. The one-year data from the European STAR-II trial will be presented by Professor Doctor Katrin Lorenz, Head of the Clinical Study Center at the Eye Clinic, Mainz University Medical Centre, Germany.
In 2020, the STAR-I and STAR-II results brought very promising news in minimally invasive glaucoma surgery. They consistently confirmed that MINIject is a remarkably effective treatment option for patients, while maintaining very positive safety outcomes
, explained Professor Denis, who was also an investigator in the STAR-II trial.
These data bring promise that soon an optimal, effective and longer-lasting treatment for patients with glaucoma may be possible, while avoiding the risks associated with more invasive eye surgery
, he added.
Both data sets will be presented as on-demand video presentations during the congress and will be available to attendees for three months, and permanently to EGS members. To register: http://www.egs2020.org/node/14
